(g) if so, what steps have been taken to check the same; and

(h) what are the names of injections which are being imported in the country which have monopoly-imports and which have annual import cost of more than Rupees one crore and what are the prices at which each is being sold ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Yes. Sir.

(b) Yes, Sir.

(c) M/s. Glaxo India Limited.

(d) Yes, Sir.

(e) Does not arise.

(f) Nothing has come to the notice of Government.

(g) Does not arise.

(h) Import of individual formulations are not being monitored by this Department.

Representations against wrong exclusion of Glybenclamide

2939. SMT. KAILASHPATI:
SMT. PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 915 given in the Rajya Sabha on 16th August, 1990 and state:

(a) what is the total number of representations received by his Ministry against wrong exclusion of Glybenclamide; and

(b) when the Standing Committee made recommendations on this drug and by when his Ministry would take a decision on these recommendations ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) About 22 representations from Hon'ble Members of Parliament have been received against exclusion of Glybenclamide from price control. The recommendation of the Standing Committee on this is under Governments' consideration.

Price control on small scale units

2940. SHRIMATI KAILASHPATI:
SHRIMATI PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1425 given in the Rajya Sabha on 20th August, 1990 and state:

(a) whether it is a fact that the Kelkar Committee made certain observations about the functioning of Small Scale Units and their effect on consumer pricing:

(b) what is the reaction of his Ministry on those observations;

(c) whether it is a fact that Kelkar Committee recommended for price decontrol of Small Scale Units with turn over limitations;

(d) whether it is also a fact that Committee gave logical reasoning in support of their recommendations;

(e) what were the reasons for which his Ministry did not accept the Committee's recommendations:

(f) whether it is a fact that the value of production of bulk drugs is based on selling prices and value of imports on CIF prices; and

(g) what is the ex-factory value of production of bulk drugs for the last three years, yearwise ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Yes, Sir.

(b) This is being examined in the review of the current policy.

(c) and (d) Yes, Sir.

(e) Keeping in view various suggestions including recommendations made by the National Drugs and Pharmaceuticals Development Council (NDPDC), Government took an independent decision to grant exemption to small scale units in respect of Category II formulations.

(f) No, Sir.

(g) It is already given in reply to Rajya Sabha Unstarred Question No. 1425 answered on 20-8-1990.

Prices of Flagyle range of formulations

2941. SMT. KAILASHPATI:

SMT. PRATIBHA SINGH:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Starred Question 159 given in the Rajya Sabha on 20th August, 1990 and state:

(a) when were the prices of Flagyle range of formulations fixed by his Ministry under DPCO, 1979 and DPCO, 1987 and what price was fixed for each;

(b) what was the price of bulk drug taken in fixation of formulation prices based on Metronidazole;

(c) what are the names of formulations being marketed by Unique Chem. Reptakos Brott, Fairdeal, Unichem and Unique Pharma and when the prices of each strength and each pack of their brands were fixed under DPCO, 1979 and DPCO, 1987 and what are the prices at which each is being sold at present;

(d) whether it is a fact that most of these companies are marketing these formulations without price approval; and

(e) if so, what are the details thereof and what action has been taken thereon ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) The requisite information, to the extent available, is given in the annexed statement. (*See below*).

(c) to (e) The information to the extent available is being collected and will be laid on the Table of the House.

Statement

Sl. No.	Name of Formulation	Pack Size	Price Fixed with Date		Bulk Drug price adopted
			Under DPCO, 1979 (Rs.)	Under DPCO, 1987 (Rs.)	
1	Metronidazole Tablets (Flagyl) 200 mg.	10's	2·84 (5-5-86)	3·32 (7-11-89)	520·56/Kg.
2	Do. 400 mg. . .	10's	4·83 (5-5-86)	5·60 (7-11-89)	520·56/Kg.
3	Metronidazole Suspension (Met. Benzoxylate) 200 mg/5 ml	30 ml	N.A.	5·66 (7-11-89)	551·88/Kg.
4	Do.	60 ml	N.A.	13·03 (8-11-89)	521·56/Kg.
5	Flagyl IV Inj.	100 ml	N.A.	13·03 (8-11-89)	520·56/Kg.
6	Flagyl F. Tabs. Metronidazole 200 mg. + Furazolidone 100 mg.	10's	N.A.	4·44 (27-7-89)	520·56/Kg.
7	Flagyl F. Susp. Benzoyl Met. 100 mg. + Furazolidone 30 mg.	60 ml	N.A.	7·76 (27-7-89)	551·88/Kg.